REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 5-6, 2024, in New York, New York. Management will participate in a fireside chat on Wednesday, June 5, 2024, at 11:30 am ET. A live webcast of the event will be available here and in the Investor Relations section of the Company's website, http://ir.codexis.com. A replay will be archived ...

For More Information The panel will take place on Wednesday, May 22, 2024, at 4:25 pm ET. A live webcast of the event will be available here and in the Investor Relations section of the Company's website, https://www.codexis.com/investors. A replay will be archived for 90 days following the event. About Codexis Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of prote ...

REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, "Sustainable API Manufacturing" at the TD Cowen 2nd Annual Sustainability Week, being held virtually May 21-23, 2024. During the presentation, Management will highlight the potential benefits of an enzymatic route of synthesis in the manufacture of small molecule and siRNA therapeutics. Codexis is a leading enzym ...

Financial Data and Key Metrics Changes - Total revenues for Q1 2024 were $17.1 million, a 32% increase from $13 million in the prior year [50] - Product revenues increased by 14% to $9.6 million in Q1 2024, compared to $8.4 million in Q1 2023 [50] - R&D revenues rose to $7.5 million in Q1 2024 from $4.6 million last year, driven by a $6 million license agreement with Roche [40] Business Line Data and Key Metrics Changes - Product gross margin improved to 49% in Q1 2024, up from 46% in Q1 2023 [40] - Approximately 5% of Q1 2024 product revenue came from enzyme supply and other commercially approved products, while 19% was from generics [59] - The concentration of product sales from the top three commercial pharma products decreased from 72% in Q1 2023 to 37% in Q1 2024, indicating progress in diversifying the revenue base [41][65] Market Data and Key Metrics Changes - The company is currently supplying enzymes for about 12 named programs in Phase 2 and Phase 3, and for 16 commercial drugs [65] - The company expects to recognize a large customized double-stranded RNA ligase order by the end of the year, contributing to future revenues [60] Company Strategy and Development Direction - The company is focused on expanding its customer base and filling its pipeline to sustain future annual double-digit product revenue growth throughout the decade [27] - Plans for the ECO Synthesis Innovation Lab are on track, expected to be largely built out by the end of the year, which will enhance manufacturing capabilities [11] - The company aims to offer a completely enzymatic process with enzymatically synthesized raw materials, supporting the transition to large-scale GMP manufacturing [56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in reiterating full-year 2024 guidance, expecting at least 10% year-on-year growth in product revenue [4] - The company anticipates Q2 to be the lowest quarter of the year, with a strong second half expected [52] - Management highlighted increasing customer interest in enzymatic approaches to reduce manufacturing costs and overcome challenges in synthesizing longer RNA constructs [35] Other Important Information - The company ended Q1 2024 with cash and cash equivalents of $85 million, expected to fund operations through positive cash flow anticipated around the end of 2026 [61] - R&D expenses for Q1 2024 were $11.2 million, down from $16.7 million last year, reflecting cost control measures [58] Q&A Session Summary Question: Progress of pharma manufacturing customers - The company is currently supplying enzymes for about 12 named programs in Phase 2 and Phase 3, with a goal to expand to around 67 customers [65] Question: Details on the double-stranded RNA ligase order - The order came from an existing customized program, and the customer found the company's ligation enzyme significantly better than their previous choice [92] Question: Updates on life science enzymes - The company is exploring potential out-licensing opportunities with remaining life science enzymes, with progress expected in the current quarter [63] Question: Expectations for the new ligase screening service - The screening service is designed to provide customers with superior enzymes, and the company anticipates it will lead to additional orders as customers scale up [110]

| --- | --- | --- | |------------------------------|-------|----------------------| | | | | | | | | | | | | | May 2, 2024 Q1 2024 Results | | | | | | We engineer enzymes | 1 Actual results could differ materially from Codexis' current expectations for a variety of reasons, including due to the factors set forth in Codexis' most recently filed periodic report, including under the caption "Risk Factors," and Codexis' other current and periodic reports filed with the SEC. If any of these risks or uncertainties ...

• We use hazardous materials in our business, and we must comply with environmental laws and regulations. • We may be involved in lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming and unsuccessful. Biotherapeutic programs are highly regulated and expensive, and our enzyme products are complex and subject to quality control requirements. The ability of our customers, future customers or collaborators, including any company developing RNAi therapeutics, ...

Exhibit 99.1 Codexis Reports First Quarter 2024 Financial Results Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer Company is in Final Stages of Enzymatically Synthesizing a Full-Length Oligonucleotide with ECO Synthesis™ Manufacturing Platform and will Provide Update at TIDES USA Meeting REDWOOD CITY, Calif., May 2, 2024 -- Codexis, Inc. (NASDAQ: CDXS), a leading ...

REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company's Strategic Advisory Board (SAB). Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences, a bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications. Her deep biotechnology experience includes leadership roles across fermentation-based commercial manufactu ...

Codexis, Inc. (NASDAQ:CDXS) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET Company Participants Carrie McKim - Director of IR Stephen Dilly - President and CEO Kevin Norrett - COO Sri Ryali - CFO Stefan Lutz - SVP of Research Conference Call Participants Brandon Couillard - Jefferies Evan Stampler - Stifel Steven Mah - TD Cowen Jacob Johnson - Stephens Matthew Hewitt - Craig-Hallum Capital Group Operator Welcome to the Codexis Fourth Quarter and Full Year 2023 Earnings Conference Call. [Opera ...

Codexis (CDXS) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 112.50%. A quarter ago, it was expected that this producer of custom industrial enzymes would post a loss of $0.32 per share when it actually produced a loss of $0.26, delivering a surprise of 18.75%.Over the last fo ...